The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | FLT3 mutation clearance rate in patients with newly diagnosed AML
In this video, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares an update on the impact of FLT3 mutation clearance in patients with newly diagnosed acute myeloid leukemia (AML) treated with gilteritinib plus azacitidine or azacitidine monotherapy. As part of the LACEWING trial (NCT02752035), Dr Wang explains that a sensitive next-generation sequencing assay was used to analyze mutation clearance rate in the two patient groups, and reports on the results from this analysis. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
